Table 1.
Characteristics of European American participants by Presence or Absence of CHD in the FamHS
| with CHD | without CHD | P value | |
|---|---|---|---|
| Sample size | 327 | 2,429 | |
| Men | 233 | 1003 | <.0001 |
| Age (years) | 68.1 ± 9.1 | 55.6 ± 13.1 | <.0001 |
| FL (HU) | −57.5 ± 11.6 | −59.4 ± 11.1 | 0.0047 |
| FL ≥ −40 HU* (NTotal; % of affected) | 25 (311; 8.0) | 152 (2,328; 6.5) | 0.056 |
| ALT≥40U/L* (NTotal; % of affected) | 24 (312; 7.7) | 138 (2,314; 6.0) | 0.046 |
| BMI (kg/m 2) | 29.8 ± 5.1 | 28.7 ± 5.7 | 0.0004 |
| HOMA-IR | 4.10 ± 4.85 | 2.64 ± 2.46 | <.0001 |
| Diabetes (NTotal; % of affected) | 103 (327; 31.5) | 263 (2,427; 10.8) | <.0001 |
| LDL-C (mg/dL) | 92.1 ± 30.3 | 113.3 ± 33.4 | <.0001 |
| Lipid-lowering medication (NTotal; % of affected) | 207 (308; 67.2) | 420 (2,334; 18.0) | <.0001 |
| SBP (mm Hg) | 125.6 ±22.4 | 120.2 ±19.6 | <.0001 |
| DBP (mm Hg) | 68.3 ± 10.1 | 70.0 ± 9.8 | 0.0055 |
| Antihypertensive medication (NTotal; % of affected) | 203 (327; 62.1) | 655 (2,425; 27.0) | <.0001 |
Variables are shown as number (N), and/or frequency (%), or mean ± standard deviation;
P values refer to t-test for continuous variables and χ2 test for categorical variables;
FL: Fatty liver (liver attenuation * −1); ALT: levels of alanine transaminase; BMI: body mass index; HOMA-IR: Homeostatic Model Assessment (fasting glucose (mmol/L)*fasting insulin (mU/L)/22.5); Diabetes: taking hyperglycemic medication and/or fasting glucose≥ 126 ml/dl); LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; SBP: diastolic blood pressure;
*
Fisher’s Exact Test (table probability)